Toxicity of LY303366, an echinocandin antifungal, in mice pretreated with glucocorticoids

Antimicrobial Agents and Chemotherapy

Volumn 44, Issue 2, 2000, Pages 378-381

  Clemons, Karl V ^a,b,c   Sobel, Raymond A ^d,e   Stevens, David A ^a,b,c  

^a CALIFORNIA INSTITUTE FOR MEDICAL RESEARCH   (United States)

^b SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^c STANFORD UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Sierra Pacific MIRECC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIDULAFUNGIN; ANTIFUNGAL AGENT; CORTISONE; CORTISONE ACETATE; DEXAMETHASONE; ECHINOCANDIN B DERIVATIVE; GLUCOCORTICOID; HYDROCORTISONE; TRIAMCINOLONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; FEMALE; FUNGICIDAL ACTIVITY; HISTOPATHOLOGY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STRAIN DIFFERENCE;

ANIMALS; ANTIBIOTICS, ANTIFUNGAL; ASPERGILLOSIS; DISEASE MODELS, ANIMAL; DRUG INTERACTIONS; GLUCOCORTICOIDS; MALE; MICE; MICE, INBRED DBA; PEPTIDES, CYCLIC;

EID: 0033977727     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.44.2.378-381.2000     Document Type: Article

References (12)

1. Debono, M., W. W. Turner, L. LaGrandeur, F. J. Burkhardt, J. S. Nissen, K. K. Nichols, M. J. Rodriguez, M. J. Zweifel, D. J. Zeckner, R. S. Gordee, J. Tang, and T. R. Parr. 1995. Semisynthetic chemical modification of the antifungal lipopeptide echinocandin B (ECB): structure-activity studies of the iipophilic and geometric parameters of polyarylated acyl analogs of ECB. J. Med. Chem. 38:3271-3281.
2. Espinel-Ingroff, A. 1998. Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. J. Clin. Microbiol. 36:2950-2956.
3. Krishnarao, T. V., and J. N. Galgiani. 1997. Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. 41:1957-1960.
4. Maeda, N., K. Doi, and T. Mitsuoka. 1986. Development of heart and aortic lesions in DBA/2NCrj mice. Lab. Anim. 20:5-8.
5. Munro, A. 1994. Drug toxicokinetics: scope and limitations that arise from species differences in pharmacodynamic and carcinogenic responses. J. Pharmacokinet. Biopharm. 22:41-57.
6. Nabors, C. E., and C. R. Ball. 1969. Spontaneous calcifications in the hearts of DBA mice. Anat. Rec. 164:153-161.
7. Paulus, H. E., D. E. Furst, and S. H. Droomgoole. 1987. Drugs for rheumatic diseases. Churchill Livingstone, New York, N.Y.
8. Petraitis, V., R. Petraitiene, A. H. Groll, A. Bell, D. P. Callender, T. Sein, R. L. Schaufele, C. L. McMillian, J. Bacher, and T. J. Walsh. 1998. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob. Agents Chemother. 42:2898-2905.
9. Pfaller, M. A., F. Marco, S. A. Messer, and R. N. Jones. 1998. In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus. Fusarium, Rhizopus, and other filamentous fungi. Diagn. Microbiol. Infect. Dis. 30:251-255.
10. Uzun, O., S. Kocagöz, Y. Cetinkaya, S. Arikan, and S. Unal. 1997. In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates. Antimicrob. Agents Chemother. 41:1156-1157.
11. Verweij, P. E., K. L. Oakley, J. Morrissey, G. Morrissey, and D. W. Denning. 1998. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis. Antimicrob. Agents Chemother. 42:873-878.
12. Zhanel, G. G., J. A. Karlowsky, S. A. Zelenitsky, M. A. Turik, and D. J. Hoban. 1998. Susceptibilities of Candida species isolated from the lower gastrointestinal tracts of high-risk patients to the new semisynthetic echinocandin LY303366 and other antifungal agents. Antimicrob. Agents Chemother. 42:2446-2448.